Proudfoot J - Search Results

1

Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry.

Proudfoot J, Barden A, Mori TA, Burke V, Croft KD, Beilin LJ, Puddey IB. Proudfoot J, et al. Anal Biochem. 1999 Aug 1;272(2):209-15. doi: 10.1006/abio.1999.4187. Anal Biochem. 1999. PMID: 10415090

2

PGF2-isoprostanes formed during copper-induced oxidation of low-density lipoproteins are the prostaglandins that cross-react with PGE2 antibodies.

Proudfoot JM, Beilin LJ, Croft KD. Proudfoot JM, et al. Biochem Biophys Res Commun. 1995 Jan 17;206(2):455-61. doi: 10.1006/bbrc.1995.1064. Biochem Biophys Res Commun. 1995. PMID: 7826362

3

Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men.

Loke WM, Hodgson JM, Proudfoot JM, McKinley AJ, Puddey IB, Croft KD. Loke WM, et al. Among authors: proudfoot jm. Am J Clin Nutr. 2008 Oct;88(4):1018-25. doi: 10.1093/ajcn/88.4.1018. Am J Clin Nutr. 2008. PMID: 18842789 Free article. Clinical Trial.

4

HDL is the major lipoprotein carrier of plasma F2-isoprostanes.

Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA. Proudfoot JM, et al. J Lipid Res. 2009 Apr;50(4):716-22. doi: 10.1194/jlr.M800607-JLR200. Epub 2008 Dec 2. J Lipid Res. 2009. PMID: 19050315 Free PMC article.

5

F₂-Isoprostanes in HDL are bound to neutral lipids and phospholipids.

Proudfoot JM, Barden AE, Croft KD, Galano JM, Durand T, Bultel-Poncé V, Giera M, Mori TA. Proudfoot JM, et al. Free Radic Res. 2016 Dec;50(12):1374-1385. doi: 10.1080/10715762.2016.1250262. Epub 2016 Nov 7. Free Radic Res. 2016. PMID: 27750456

6

Phenolic content of various beverages determines the extent of inhibition of human serum and low-density lipoprotein oxidation in vitro: identification and mechanism of action of some cinnamic acid derivatives from red wine.

Abu-Amsha R, Croft KD, Puddey IB, Proudfoot JM, Beilin LJ. Abu-Amsha R, et al. Among authors: proudfoot jm. Clin Sci (Lond). 1996 Oct;91(4):449-58. doi: 10.1042/cs0910449. Clin Sci (Lond). 1996. PMID: 8983870

7

Unexpected dose response of copper concentration on lipoprotein oxidation in serum: discovery of a unique peroxidase-like activity of urate/albumin in the presence of high copper concentrations.

Proudfoot JM, Puddey IB, Beilin LJ, Stocker R, Croft KD. Proudfoot JM, et al. Free Radic Biol Med. 1997;23(5):699-705. doi: 10.1016/s0891-5849(97)00021-x. Free Radic Biol Med. 1997. PMID: 9296445

8

The role of copper reduction by alpha-tocopherol in low-density lipoprotein oxidation.

Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Proudfoot JM, et al. Free Radic Biol Med. 1997;23(5):720-8. doi: 10.1016/s0891-5849(97)00015-4. Free Radic Biol Med. 1997. PMID: 9296448

9

Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1.

Proudfoot JM, Croft KD, Puddey IB, Beilin LJ. Proudfoot JM, et al. J Pharmacol Exp Ther. 2003 Jun;305(3):846-53. doi: 10.1124/jpet.102.047795. Epub 2003 Mar 6. J Pharmacol Exp Ther. 2003. PMID: 12626661

10

Effects of alpha-tocopherol and mixed tocopherol supplementation on markers of oxidative stress and inflammation in type 2 diabetes.

Wu JH, Ward NC, Indrawan AP, Almeida CA, Hodgson JM, Proudfoot JM, Puddey IB, Croft KD. Wu JH, et al. Clin Chem. 2007 Mar;53(3):511-9. doi: 10.1373/clinchem.2006.076992. Epub 2007 Feb 1. Clin Chem. 2007. PMID: 17272491 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

754 results

Search Page

Filters